Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma

Head and Neck

Volumn 29, Issue 4, 2007, Pages 341-350

  Speleman, Luciënne ^a   Kerrebijn, Jeroen D F ^a   Look, Maxime P ^a   Meeuwis, Cees A ^a   Foekens, John A ^a   Berns, Els M J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Invasion; PAI 1; Perineural; uPA

Indexed keywords

CATHEPSIN D; MYC PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MALE; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CATHEPSIN D; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 34247261470     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20527     Document Type: Article

References (73)

1. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-159.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
3. Visser. Feiten en fables over kanker in Nederland. Vereniging van integraal kanker centra. 2000.
4. Vaamonde P, Martin C, del Rio M, LaBella T. Second primary malignancies in patients with cancer of the head and neck. Otolaryngol Head Neck Surg 2003;129:65-70.
5. Dhooge IJ, De Vos M, Van Cauwenberge PB. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998;108:250-256.
6. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 1993;71:452-456.
7. Johnson NW, Warnakulasuriy S, Tavassoli M. Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Eur J Cancer Prev 1996;5:5-17.
8. Gandour-Edwards R, Trock B, Donald PJ. Predictive value of cathepsin-D for cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 1999;21:718-722.
9. Fagan JJ, Collins B, Barnes L, D'Amico F, Myers EN, Johnson JT. Perineural invasion in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1998;124:637-640.
10. Rahima B, Shingaki S, Nagata M, Saito C. Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:423-431.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
12. Barbareschi M, Gasparini G, Morelli L, Forti S, Dalla Palma P. Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 1995;36:181-192.
13. Bajou K, Lewalle JM, Martinez CR, et al. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 2002;100:501-506.
14. Sier CF, Vloedgraven HJ, Ganesh S, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994;107: 1449-1456.
15. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-928.
16. Fletcher GH, Evers WT. Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology 1970;95:185-188.
17. Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH, editors. Illustrated guide to TNM/ pTNM classification of malignant tumours. Berlin: Springer Verlag; 2005.
18. Breast Cancer Cooperative Group. Revision of standards of for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980;16:1513-1515.
19. Ronne E, Hoyer-Hansen G, Brunner N, et al. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995;33: 199-207.
20. Grondahl-Hansen J, Peters HA, van Putten WL, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-1087.
21. Foekens JA, Buessecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995;55: 1423-1427.
22. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992;28:697-700.
23. Barlow RE, Batholomew D, Bremner J. Statistical Inference Under Order Restrictions. London: Wiley; 1972.
24. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
25. Yasuda T, Sakata Y, Kitamura K, Morita M, Ishida T. Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Head Neck 1997;19:611-616.
26. Zeillinger R, Eder S, Schneeberger C, Ullrich R, Speiser P, Swoboda H. Cathepsin D and PAI-1 expression in human head and neck cancer. Anticancer Res 1996;16: 449-453.
27. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer 1998;34:1193-1197.
28. Parolini S, Flagiello D, Cinquetti A, et al. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 1996;74: 1168-1174.
29. Itaya T, Suzuki K, Takagi I, Motai H, Baba S. Relationship between head and neck squamous cell carcinomas and fibrinolytic factors. Immunohistological study. Acta Otolaryngol Suppl 1996;525:113-119.
30. Nozaki S, Endo Y, Kawashiri S, et al. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol 1998;34:58-62.
31. Pacheco MM, Kowalski LP, Nishimoto IN, Brentani MM. Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs. Head Neck 2002;24:24-32.
32. Petruzzelli GJ, Snyderman CH, Johnson JT. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1994;120:989-992.
33. Clayman G, Wang SW, Nicolson GL, et al. Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer 1993; 54:73-80.
34. Chin D, Boyle GM, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005;113:789-797.
35. Hundsdorfer B. The prognostic importance of uPA and PAI-1 in the primary resection of oral squamous cell carcinoma. Mund Kiefer Gesichtschir 2004;8:173-179.
36. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res 2000;20:3975-3981.
37. Hundsdorfer B, Zeilhofer HF, Bock KP, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33:191-196.
38. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O'Higgins NJ. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998;44:1177-1183.
39. Schmitt M. The plasminogen activation system as a novel target for therapeutic strategies. Fibrinolysis 2000;14: 114-132.
40. Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-123.
41. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
42. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997;78:285-296.
43. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999;71:130-135.
44. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-643.
45. Janicke F, Schmitt M, Graeff H. Clinical relevence of urokinase type and tissue-type plasminogen activators and their inhibitor PAI in breast cancer. Semin Thromb Hemost 1991;17:303-312.
46. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-920.
47. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999;107:54-61.
48. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001;152:741-752.
49. Offersen BV, Nielsen BS, Hoyer-Hansen G, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 2003;163:1887-1899.
50. Illemann M, Hansen U, Nielsen HJ, et al. Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol 2004;122: 256-265.
51. Usher PA, Thomsen OF, Iversen P, et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005;113:870-880.
52. Benraad TJ, Geurts-Moespot J, Grondahl-Hansen J, et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer A 1996;32:1371-1381.
53. O'Brien CJ, Lahr CJ, Soong SJ, et al. Surgical treatment of early-stage carcinoma of the oral tongue - would adjuvant treatment be beneficial? Head Neck Surg 1986;8:401-408.
54. Soo KC, Carter RL, O'Brien CJ, Barr L, Bliss JM, Shaw HJ. Prognostic implications of perineural spread in squamous carcinomas of the head and neck. Laryngoscope 1986;96:1145-1148.
55. Close LG, Brown PM, Vuitch MF, Reisch J, Schaefer SD. Microvascular invasion and survival in cancer of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg 1989;115:1304-1309.
56. Lydiatt DD, Robbins KT, Byers RM, Wolf PF. Treatment of stage I and II oral tongue cancer. Head Neck 1993;15: 308-312.
57. Maurizi M, Almadori G, Cadoni G, et al. Cathepsin D concentration in primary laryngeal cancer: correlation with clinico-pathologic parameters, EGFR status and prognosis. Int J Cancer 1996;69:105-109.
58. Grandori C, Eisenman RN. Myc target genes. Trends Biochem Sci 1997;22:177-181.
59. Thompson EB. The many roles of c-Myc in apoptosis. Annu Rev Physiol 1998;60:575-600.
60. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998;12:633-651.
61. Merritt WD, Weissler MC, Turk BF, Gilmer TM. Oncogene amplification in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1990;116:1394-1398.
62. Leonard JH, Kearsley JH, Chenevix-Trench G, Hayward NK. Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer 1991;48:511-515.
63. Haughey BH, von Hoff DD, Windle BE, Wahl GM, Mock PM. c-myc oncogene copy number in squamous carcinoma of the head and neck. Am J Otolaryngol 1992;13: 168-171.
64. Rodrigo JP, Lazo PS, Ramos S, Alvarez I, Suarez C. MYC amplification in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1996; 122:504-507.
65. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-1975.
66. de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A. CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck 2001;23:104-112.
67. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003;63:1179-1182.
68. Waitzberg AF, Nonogaki S, Nishimoto IN, et al. Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. Cancer Detect Prev 2004;28:178-186.
69. Gapany M, Pavelic ZP, Kelley DJ, et al. Immunohistochemical detection of c-myc protein in head and neck tumors. Arch Otolaryngol Head Neck Surg 1994;120: 255-259.
70. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989;4:1463-1468.
71. Porter MJ, Field JK, Leung SF, et al. The detection of the c-myc and ras oncogenes in nasopharyngeal carcinoma by immunohistochemistry. Acta Otolaryngol 1994;114: 105-109.
72. Yu Y, Dong W, Li X, Yu E, Zhou X, Li S. Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003;129: 1322-1326.
73. Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol 1995;31:384-391.